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Viroj Wiwanitkit1,2,3,4*An important medical disorder that is common but not
successfully managed in the present day is cancer. In
fact, cancer has been known in medicine for many cen-
turies. Continuous attempt to find anti-neoplastic drug
leads to several ant-cancer drugs at present. However, as
noted, the actual effective drug is still not available.
Hence, cancer is still a deadly disease. Finding for new
anti-neoplastic drug is the focus in cancer research at
present. In the process, after developing of new drug
alternatives, the next step is to study on its efficacy. Ba-
sically, the evaluation on pharmacological and toxico-
logical effects has to be done for confirming the
effectiveness and safety of the new drug. To serve this
purpose, the in vitro model study is generally gone as
the pioneer step. It is also the basic requirement for fur-
ther drug registration [1]. Focusing on the vitro model
study, there are some facts to be addressed. First, the
model is not an actual thing. It is only the attempt to
simulate the real phenomenon. Second, the study is gen-
erally in vitro. This is for the safety reason. In vitro study
means the experiment outsides the living things. Hence,
an in vitro study is totally not the real case in human
beings. In general, the better study can be done based
on in vivo study only if the safety is completely con-
firmed. It should be further noted that in vivo study can
also be either in animal model or real human subjects.
The best interpretation has to be based on finding for
human study. Nevertheless, the human study has the
highest risk comparing to the other techniques. Focusing
on the new anti-neoplastic drug, it is perceived as a dan-
gerous chemical agent. Hence, it is rarely studied in
human subjects. Also, it is very hard to include cancer-
ous patients to enroll in such study and it should be un-
ethical to perform such experiment in normal subjects.
Furthermore, any studies have to follow the good re-
search guideline. The use of randomized control trial isCorrespondence: wviroj@yahoo.com
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reproduction in any medium, provided the orusually preferable for final acceptance on registration
process [2]. Finally, the present in vitro model study also
poses the pitfall. Most in vitro model for the novel anti-
neoplastic drug test is based on the cell culture, which is
usually transformed neoplastic cell type [3]. Those trans-
formed cell is not normal physiological cells, hence, the
normal physiological response to the studied chemical
agent cannot be expected. Those cancerous cells might
not respond well or tolerate to side effect [3].
Considering the present in vitro cell culture study for
new anti-neoplastic agent, several facts should be dis-
cussed. First, as already noted, the observation on the
drug study is derived from abnormal transformed cells
which usually passed several biomedical modification
and sub-culture process. This cannot directly and totally
imply the normal cells and non transformed, non sub-
cultured cancerous cells. To refer for effectiveness and
safety for further human study or usage must be careful.
Second, in vitro model cannot include any biotrans-
formation that might occur in vivo. Drug distribution,
drug elimination and interference from other biochem-
ical substances in human body are all not studied in the
vitro test. Third, it should be noted that several new
anti-neoplastic alternative are developed with advanced
biomedical engineering technology [4], such as recom-
binant protein technology and nanopharmacology. Since
the medical society still has few information on the side
effect of those new substances (new recombinants, new
nanomaterials, etc.). The complete study on the toxico-
logical effect is required. For the new nano-anti-neoplastic
drug, the drug in vitro might totally not reflect the actual
action in human body. Since the nanomaterial is highly
sensitive, it might aggregate to form larger molecule
in vivo or it might interact with several substances,
especially for proteins, in human body. For sure, if such
scenario occur, the change in pharmacological and toxico-
logical properties is possible. The development of new
drug test system for nanomaterial – based anti-neoplastic
drug is required and the test must be performed within
certified nanotechnology laboratory. Fourth, it must bed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Wiwanitkit DARU Journal of Pharmaceutical Sciences 2012, 20:65 Page 2 of 2
http://www.darujps.com/content/20/1/65repeatedly noted that anti-neoplastic agent is chemical
hazardous. The safety concern should be for not only the
patients but also on the medical personnel who develop
and perform drug test. The safety of the practitioners
seems to be the forgotten issue. Finally, the new alterna-
tive mean to test the new drug should be mentioned.
With advanced computational technology, the use of
bioinformatics tool to help simulate and study on the
drug pharmacology and toxicology is possible.
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